Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL
Status:
Completed
Trial end date:
2020-10-06
Target enrollment:
Participant gender:
Summary
Objectives of this clinical trial are to evaluate the safety, tolerability, pharmacokinetics
and potential efficacy of the investigational drug, cobomarsen (MRG-106), in patients
diagnosed with certain lymphomas and leukemias, including cutaneous T-cell lymphoma (CTCL)
[mycosis fungoides (MF) subtype], chronic lymphocytic leukemia (CLL), diffuse large B-cell
lymphoma (DLBCL) [activated B-cell (ABC) subtype], and adult T-cell leukemia/lymphoma (ATLL).
Cobomarsen is an inhibitor of a molecule called miR-155 that is found at high levels in these
types of cancers and may be important in promoting the growth and survival of the cancer
cells. Participants in the clinical trial will receive weekly doses of cobomarsen
administered by injection under the skin or into a vein, or by injection directly into
cancerous lesions in the skin (for CTCL only). Blood samples will be collected to measure how
cobomarsen is processed by the body, and other measurements will be performed to study how
normal and cancerous cells of the immune system respond when exposed to cobomarsen.